Form 4: Dyne Therapeutics Executive Sells Shares
Insider Transaction (Form 4)
Johanna Friedl-Naderer, Chief Commercial Officer of Dyne Therapeutics, Inc., sold 1,085 shares of common stock on September 4, 2026.
Summary
- Open-market sale: disposed of 900 Common Stock at $24.35 ($21,915) on September 4, 2026; holds 153,082 after (Direct).
- Open-market sale: disposed of 185 Common Stock at $18.88 ($3,493) on September 8, 2026; holds 152,897 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $25,408 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Johanna Friedl-Naderer — Officer (Chief Commercial Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-04 | Open-market sale | Common Stock | 900 | $24 | $21.9K | 153,082 |
| 2026-09-08 | Open-market sale | Common Stock | 185 | $19 | $3.5K | 152,897 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-04 | Open-market sale (900 shares) |
| 2026-09-08 | Open-market sale (185 shares) |
Keywords
insider transaction, Form 4, DYN, Dyne Therapeutics, Inc., bearish, Johanna Friedl-Naderer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.